FDA warns Nikkiso Medical America that its DBB-06 dialysis device with unapproved automated blood-volume control is adulterated and misbranded.
What happened
FDA reviewed Nikkiso's marketing materials on February 5, 2021, including an online product brochure. FDA found claims that the DBB-06 Haemo-Master Blood Volume Monitor uses "adaptive feedback" to regulate blood volume trend and automatically change fluid removal, a physiological closed loop controller (PCLC) function. FDA says this PCLC function was not described in the 510(k) summaries or indications for K091978 and K152938 and that FDA had told the firm in 2019 that the function was not cleared.
What FDA found
FDA says the DBB-06 with PCLC is adulterated because Nikkiso lacks an approved premarket approval (PMA) or investigational device exemption (IDE) for that function.
section 501(f)(1)(B), 21 U.S.C. § 351(f)(1)(B); section 515(a), 21 U.S.C. § 360e(a); section 520(g), 21 U.S.C. § 360j(g)FDA says the device is misbranded because Nikkiso made a significant change by adding PCLC without submitting a new 510(k) premarket notification.
section 502(o), 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k); 21 CFR 807.81(a)(3)FDA says Nikkiso's online brochure claims the Blood Volume Monitor uses "adaptive feedback" to regulate blood volume trend and automatically change fluid removal.
FDA says the 510(k) summaries and indications for K091978 and K152938 do not describe PCLC, unlike Nikkiso's current marketing.
FDA says it previously told Nikkiso in 2019 that the adaptive feedback controller was not cleared, but the firm still marketed it.
What FDA wants
FDA asks Nikkiso to immediately stop activities that cause misbranding or adulteration, including commercial distribution of the DBB-06 with PCLC, and to respond in writing within 15 business days with corrections, corrective actions, and a timetable.
Who should pay attention
- dialysis clinics and clinicians using DBB-06 devices
- distributors of Nikkiso dialysis equipment
- device firms adding automated therapy features without new clearance
This is a summary. Read the original letter on fda.gov.